Squarepoint’s Adicet Bio ACET Stock Holding History

Squarepoint’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-15,254	Closed	-$132K	–	4360
2026 Q2	$132K	Buy	+15,254	New	+$120K	﹤0.01%	4156
2026 Q1	–	Sell	-55,723	Closed	-$469K	–	4193
2025 Q4	$469K	Buy	55,723 +52,821	+1,820%	+$584K	﹤0.01%	3268
2025 Q3	$37.6K	Buy	+2,902	New	+$34.2K	﹤0.01%	4250
2025 Q2	–	Sell	-723	Closed	-$8.73K	–	4429
2025 Q1	$8.73K	Sell	723 -10,799	-94%	-$154K	﹤0.01%	4461
2024 Q4	$177K	Buy	+11,522	New	+$217K	﹤0.01%	4513
2024 Q3	–	Sell	-22,639	Closed	-$438K	–	4046
2024 Q2	$438K	Buy	22,639 +21,839	+2,730%	+$585K	﹤0.01%	3179
2024 Q1	$30.1K	Sell	800 -965	-55%	-$39.9K	﹤0.01%	3903
2023 Q4	$53.4K	Buy	1,765 +114	+7%	+$2.49K	﹤0.01%	3841
2023 Q3	$36.2K	Buy	1,651 +941	+133%	+$33.2K	﹤0.01%	3663
2023 Q2	$27.6K	Sell	710 -264	-27%	-$23.3K	﹤0.01%	3477
2023 Q1	$89.8K	Sell	974 -40	-4%	-$5.02K	﹤0.01%	2987
2022 Q4	$145K	Buy	+1,014	New	+$253K	﹤0.01%	2882
2020 Q3	–	Sell	-545	Closed	-$131K	–	2442
2020 Q2	$131K	Buy	+545	New	+$107K	﹤0.01%	1951

Other funds holding ACET

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Squarepoint's ACET Position: Q3 2026 in Review

Squarepoint sold out of Adicet Bio (ACET) in Q3 2026, closing a stake of 15,254 shares — an estimated $132K sold.

Squarepoint first reported a position in ACET in Q2 2020 and held it in 13 quarters. The position peaked at $469K in Q4 2025. 24 funds tracked by Wall St. Rank hold ACET as of Q3 2026.

Squarepoint reported no remaining Adicet Bio position as of Q3 2026 after selling out during the quarter.
Squarepoint sold 15,254 Adicet Bio shares in Q3 2026, an estimated $132K.
Squarepoint first reported a position in Adicet Bio in Q2 2020 and held it in 13 quarters.
Squarepoint's Adicet Bio position peaked at $469K in Q4 2025.
24 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.